Emavusertib
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-16 — Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.: LUCAS phase-2 open-label multicenter trial stopped at interim futility: no HI-E responses in lower-risk MDS/MDS-MPN, with 15 SAEs and 4 deaths, indicating IRAK4 inhibition does not reverse anemia in this population and carries a non-trivial safety burden. (novelty: 3)
Open questions
Related
Contributing findings
Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.
16-sep-2026
novelty 3
per-area 3
weakens